Approximately 30–50% of CRC tumours have a mutated KRAS gene, which indicates that up to 50% of the patients with this type of cancer could respond to therapy with antireceptor antibodies against the epidermal growth factor, EGFR. The gene discussed is KRAS; the disease is cancer.